RTSN Stock Forecast: Retension Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$13
−6.34% on the day

The median 12-month analyst price target for Retension Pharmaceuticals, Inc. is $50. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 18 Nov 2026 — in the weakest quartile.

Market cap
$108.4M
Ticker Nerd rank
1/ 100
Median analyst target
$50
Analysts covering
3
Total return, dividends reinvested
1W
+6.2%
1M
−20.3%
From high
−20.3%
From low
+23.6%
$11
$16
Range since 9 Oct 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Retension Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
1/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
22
Value
13
Growth
10
Quality
5
Momentum
5
Accruals
5
Volatility
4
Issuance
1

Revisions (22): Analysts have, on balance, been raising their forecasts.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RTSN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RTSN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 9 Oct 2026Adjusted close, US dollars
$10$20$30$40$50$60Oct 26Oct 26Oct 26Nov 26Nov 26Nov 26RTSNHigh $55Median $50Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$50
Low
$50
Median
$55
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Nov 2026OppenheimerInitiatesOutperform$50
2 Nov 2026GuggenheimInitiatesBuy$55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RTSN.

Market Radar

This page is one stock. Monday covers all of them.

RTSN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RTSN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

RTSN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 26Oct 26Oct 26Nov 26Nov 26Nov 26RTSNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RTSN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
—
Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Retension Pharmaceuticals, Inc. has a market value of $108.4M and an enterprise value of $25.9M.

  • Shares outstanding: 8.3M.

  • Retension Pharmaceuticals, Inc. employs 12 people.

market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

RTSN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RTSNRetension Pharmaceuticals, Inc.$108.4M1
ARMPArmata Pharmaceuticals, Inc.$116.1M86
SPRBSpruce Biosciences, Inc.$117.4M10
UPBUpstream Bio, Inc.$113.9M20
OKUROnKure Therapeutics, Inc.$113.9M52
IMUXImmunic, Inc.$119.4M19
NTHINeOnc Technologies Holdings, Inc.$119.8M31

Take a look at RTSN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Retension Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RTSN

What is the RTSN stock price forecast for 2026-2027?

The median 12-month analyst price target for Retension Pharmaceuticals, Inc. is $50, with estimates ranging from $50 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RTSN stock a buy right now?

Of the 3 analysts covering Retension Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Retension Pharmaceuticals, Inc. 1 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RTSN?

As at 18 Nov 2026, Retension Pharmaceuticals, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (22 of 100).

Will RTSN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $50, and Ticker Nerd's factor model ranks Retension Pharmaceuticals, Inc. 1 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RTSN stock forecast for 2030?

No analyst covering Retension Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RTSN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $55 over the next 12 months.

What does Retension Pharmaceuticals, Inc. do?

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and related cardiovascular disorders. Its lead product candidate, RTN-001, is an orally administered, once-daily PDE5 inhibitor being evaluated for patients with uncontrolled or resistant hypertension.

Company

About Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and related cardiovascular disorders. Its lead product candidate, RTN-001, is an orally administered, once-daily PDE5 inhibitor being evaluated for patients with uncontrolled or resistant hypertension. The company’s work centers on addressing persistent blood-pressure management challenges through pharmaceutical development and clinical research. Retension Pharmaceuticals, Inc. operates within the cardiovascular therapeutics market, serving the broader healthcare ecosystem of patients, physicians, research institutions, and pharmaceutical partners. Based in Virginia, the company represents a specialized biotechnology business whose activities are concentrated on advancing a targeted drug candidate through clinical development rather than marketing an established portfolio of commercial medicines. Its market role is tied to the development of potential treatment options for hypertension, a widespread cardiovascular condition associated with significant demands on healthcare systems and long-term disease management.

CEO Mr. Eric Keller J.D. · 12 employees · United States · https://www.retensionpharmaceuticals.com